Oldgren J - Search Results

1

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Oldgren J, et al. Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004. Ann Intern Med. 2011. PMID: 22084332 Clinical Trial.

2

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.

Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Oldgren J, et al. Eur Heart J. 1999 Nov;20(22):1657-66. doi: 10.1053/euhj.1999.1750. Eur Heart J. 1999. PMID: 10543929 Clinical Trial.

3

Coagulation activity and clinical outcome in unstable coronary artery disease.

Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Oldgren J, et al. Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):1059-64. doi: 10.1161/01.atv.21.6.1059. Arterioscler Thromb Vasc Biol. 2001. PMID: 11397720 Clinical Trial.

4

Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.

Oldgren J, Wallentin L, Grip L, Linder R, Nørgaard BL, Siegbahn A. Oldgren J, et al. Eur Heart J. 2003 Jan;24(1):86-93. doi: 10.1016/s0195-668x(02)00312-3. Eur Heart J. 2003. PMID: 12559940 Clinical Trial.

5

Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.

Oldgren J, Siegbahn A, Grip L, Linder R, Thygesen K, Wallentin L. Oldgren J, et al. Thromb Haemost. 2004 Feb;91(2):381-7. doi: 10.1160/TH03-07-0427. Thromb Haemost. 2004. PMID: 14961168 Clinical Trial.

6

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.

James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L. James SK, et al. Among authors: oldgren j. Am Heart J. 2005 Apr;149(4):619-26. doi: 10.1016/j.ahj.2004.08.026. Am Heart J. 2005. PMID: 15990743

7

Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.

Christersson C, Oldgren J, Bylock A, Wallentin L, Siegbahn A. Christersson C, et al. Among authors: oldgren j. J Thromb Haemost. 2005 Oct;3(10):2245-53. doi: 10.1111/j.1538-7836.2005.01557.x. J Thromb Haemost. 2005. PMID: 16194202 Free article. Clinical Trial.

8

Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.

Oldgren J, Fellenius C, Boman K, Jansson JH, Nilsson TK, Wallentin L, Siegbahn A. Oldgren J, et al. J Intern Med. 2005 Nov;258(5):420-7. doi: 10.1111/j.1365-2796.2005.01562.x. J Intern Med. 2005. PMID: 16238677 Free article. Clinical Trial.

9

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.

Oldgren J, James SK, Siegbahn A, Wallentin L. Oldgren J, et al. Eur Heart J. 2007 Mar;28(6):699-704. doi: 10.1093/eurheartj/ehl565. Epub 2007 Feb 21. Eur Heart J. 2007. PMID: 17314110 Clinical Trial.

10

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.

Christersson C, Oldgren J, Bylock A, Siegbahn A, Wallentin L. Christersson C, et al. Among authors: oldgren j. Eur Heart J. 2007 Mar;28(6):692-8. doi: 10.1093/eurheartj/ehl564. Epub 2007 Feb 21. Eur Heart J. 2007. PMID: 17314111 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page